COVID-19 News

Select COVID-19 and COVID-19 Vaccine Resources

From The CDC

FDA - COVID - 19 - Notifications

SBA Options

CMS Resources

NIH COVID- 19 Information

Health & Human Services Resources

HOSS Resources & Announcements

American Cancer Society Resources & Announcements

  • American Cancer Society Cancer Action Network results of surveys on the effects of the pandemic on cancer patients and survivors, Find out more.
  • Coronavirus, COVID-19, and Cancer Resources for Patients, Find out more.
  • ACS Events Status, Find out more.

ASCO Resources & Announcements

ASH Resources & Announcements

COA Resources & Announcements

NCCN Resources & Announcements

  • NCCN Recommendations for the Use of Hematopoietic Growth Factors During COVID-19, Find out more.
  • NCCN Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community, Find out more.

HOSS Industry News regarding COVID-19

  • Agios Statement on COVID-19 and Prescribing Information for TIBSOVO, Find out more.
  • AstraZeneca Video Platform for COVID-19 Patient Communications Now Available, Find out more.
  • Bristol Myers Squibb Expands Patient Support Programs to Help Newly Uninsured Patients in the U.S., Find out more.
  • Bristol Myers Squibb: A Message to Clinical Trial Investigators on Bristol Myers Squibb’s Response to COVID-19, Find out more.
  • GSK Letter to Customers & Partners During the COVID-19 Pandemic, Find out more.
  • Guardant Health Initiatives for Patient Care During COVID-19, Find out more.
  • Johnson & Johnson: Seeking a diverse population for the Covid 19 vaccine trial called the EMSEMBLE study. Find out more here and here.
  • Johnson & Johnson: Maintaining Continuity of Care During COVID-19,Find out more.
  • Merck: Supporting Patients During the COVID-19 Pandemic, Find out more. Merck's Response to COVID-19, Find out more.
  • Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak. Find out more.
  • Pfizer is announcing preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen for potential publication. Overall, the preliminary data demonstrated that BNT162b1 could be administered in a dose that was well tolerated and generated dose dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. Find out more.
  • Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program, Find out more
  • Pfizer Information on products, patient assistance programs and medical information related to COVID-19, please click here.
  • Pfizer Outlines Five-Point Plan to Battle COVID-19, Find out more.
  • Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine, Find out more.
  • Takeda Oncology will maintain continued support of patients and health care providers, Find out more.